Metformin HCL
ID: SPE2D2-21-R-0111Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f40d1948ea214ecd93be257d692c08e7/view
Timeline
  1. 1
    Posted Jul 13, 2021, 6:53 PM UTC
  2. 2
    Updated Jul 6, 2023, 7:58 PM UTC
  3. 3
    Due Not available
Description

Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.

Files
Title
Posted
Metformin Solicitation SPE2D221R0111.pdf
Mar 28, 2024, 7:16 AM UTC
SPE2D221R0111 0001.pdf
Mar 28, 2024, 7:16 AM UTC
Lifecycle
Title
Type
Metformin HCL
Currently viewing
Presolicitation
Similar Opportunities
Metformin HCL ER
Buyer not available
Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.
6505--Metformin IR Tablets
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Metformin HCL IR Tablets as part of its pharmaceutical prime vendor programs, which also serve the Department of Defense (DoD). Offerors are required to submit pricing for various bottle sizes and quantities, ensure compliance with FDA regulations, and adhere to the Drug Supply Chain Security Act (DSCSA), including providing a unique National Drug Code (NDC) for each product. This procurement is crucial for maintaining a reliable source of pharmaceutical products, ensuring consistent availability and pricing while meeting federal regulatory standards. Interested parties should contact Senior Contract Specialist Teresa Hussain at teresa.hussain@va.gov for further details, and proposals must be submitted in accordance with the outlined requirements within the specified timeframe.
Repaglinide
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
Famotidine
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
Morphine IR & ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Morphine Immediate Release (IR) and Extended Release (ER) Tablets. The procurement will include Morphine IR in 15MG and 30MG in 100 count bottles, as well as Morphine ER in 15MG, 30MG, and 60MG in 100 count bottles, aimed at establishing a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and it will be solicited as a commercial item under FAR part 12. Interested parties should contact Christopher Newman at 445-737-7371 or christopher.newman@dla.mil for inquiries, and they are encouraged to monitor the DLA Bid Board System (DIBBS) and Sam.Gov for updates, with the projected solicitation date set for April 2025.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Valsartan
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
Pantoprazole DR Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.